Mab Designs announces publication of C20, a selective inhibitor of IL-6 trans-signalling, in Nature's Communications Biology
Mab Designs has published a peer-reviewed study in Communications Biology detailing C20, a new antibody that selectively inhibits IL-6 trans-signalling. By targeting only the inflammatory pathway while leaving classic signalling intact, the drug aims to treat inflammatory conditions without compromising host defence.
Why it matters
This development represents a potential breakthrough in precision medicine for inflammatory diseases, offering a more targeted alternative to current broad-spectrum IL-6 inhibitors.
C20 blocks human IL-6 trans-signalling while leaving classic signalling intact.
LONDON, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Mab Designs Ltd today announced the publication of a peer-reviewed study of C20, its anti-interleukin-6 trans-signalling antibody, in Communications Biology , a Nature Portfolio journal.
The paper, "Selective inhibition of IL-6 trans-signalling reveals distinct mechanisms of human classic and trans-signalling receptor-complex formation" (DOI 10.1038/s42003-026-11014-0), reports that C20 blocks human IL-6 trans-signalling while leaving classic IL-6 signalling functionally intact. The work was led by a group at Otto von Guericke University Magdeburg with Mab Designs scientists among the co-authors.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in